Interestingly, overall survival from MSKCC-CRC immunotherapy cohort was longer in the APC-WT group than in the APC-MT group (HR 2.27 (95% CI 1.05–4.88), P < 0.05) (Figure 3(c)). The gene discussed is APC; the disease is colorectal carcinoma.